CRISPR-Cas9 In Vivo Gene Editing for Transthyretin AmyloidosisJulian D. Gillmore, David Lebwohl, Jessica Seitzer et al.|New England Journal of Medicine|2021Cited by 1.7k
CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosisJulian D. Gillmore, David Lebwohl, Ed Gane et al.|Yearbook of pediatric endocrinology|2022Cited by 47
In vivo CRISPR/Cas9 editing of the TTR gene with NTLA-2001 in patients with transthyretin amyloidosis- dose selection considerationsEdward Gane, Gillmore Julian, Jörg Täubel et al.|Journal of Hepatology|2022Cited by 5